Daniel Öhlund

Happy to share that our project on the role of galectins in immune evasion has been awarded 6 MSEK in funding from the ErlingPersson Foundation. Grateful to the entire lab team and to the foundation for their support!

Back home from the Swedish Cancer Research Meeting in Malmö. Great meeting! Great contributions from our lab by Parniyan och Cedric!

Currently looking for a post-doc! umustipendie.varbi.com/en/?jobtoken=1…

@Aiims1742 @nyulangone @Perlmutter_CC Congratulations!!

🤠 👉🏽 🗽 news: I will be joining @nyulangone on September 1, 2025 as Director of the GI Cancer Center & Associate Director of Translational Research at @Perlmutter_CC. I am excited to start the next chapter of the Maitra Lab in NYC & build a strong GI cancer research program.

New paper published from our lab! Characterization of a new interferon-response CAFs with tumor-restraining properties. aacrjournals.org/cancerres/arti…

Nature research paper: MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC go.nature.com/3XPqIz1

Currently looking for a post-doc! umustipendie.varbi.com/en/what:job/jo…

🧵1/ Excited to share our latest review on how organoid technology is transforming pancreatic cancer research, published in Experimental & Molecular Medicine. Here's a breakdown of the key points. nature.com/articles/s1227…

🔥🔥 new day, 🆕 #pancreas2000 project 📣🤩 Pooled OR for pancreatic steatosis (PS) in patients with PDAC vs. controls was 3.23 (95% CI 1.86-5.60). ⬇️ ⬇️ tinyurl.com/fatpanc We need to prioritize a standardized approach to the diagnosis, follow-up, and treatment of PS.

Some highlights from the Botton-Champalimaud conference. Especially happy to see ⁦@vincorbo⁩ and ⁦@DanielOhlund⁩ continuing doing fab science. Nothing makes me happier than seeing good humans doing great. 💜💪🏻🌟

Our new review paper is out! Overcoming therapy resistance in pancreatic cancer: New insights and future directions doi.org/10.1016/j.bcp.…

The results from the NORPACT-1 trial are out! Conclusion: no survival benefit from neoadjuvant FOLFIRINOX in resectable pancreatic ductal adenocarcinoma compared with upfront surgery thelancet.com/journals/langa…

Maréne Landström, Institutionen för medicinsk biovetenskap, har utsetts till Årets cancerforskare av Cancerfondens forskningsnämnd. Det är främst upptäckten av specialiserade antikroppar, som kan förhindra att prostatacancer sprider sig, som uppmärksammas. umu.se/nyheter/umeafo…

I’m looking for a postdoc to the lab! umu.se/en/work-with-u…

Congratulations to Joshua Cumming! PhD defence @UmeaUniversity yesterday. Great discussion with opponent @claus_jorgensen.

🔥NORPACT-1: Short-course neoadjuvant FOLFIRINOX vs surgery + adj. therapy for #PDAC #ASCO23 🔎12 Nordic centers, phs-2, 140 pts 👉52% completed neoadj. CTx 🤨mOS: 25.1 mo vs 38.5 mo ✅manageable safety, but no benefit of neoadj. FOLFIRINOX @myESMO @OncoAlert

Jag är mycket hedrad över detta uppdrag 🙏🏻! Tack till @Cancerfonden och min företrädare professor Klas Kärre! ”Standing on the shoulders of giants”

Happy to join the #SwedishCancerResearchMeeting 2023!

Today is #DNADay commemorating 70 years since “Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid” was published & 20 years since the completion of the Human Genome Project. Let’s take a historical look back...🧬 dnascience.plos.org/2023/04/20/sev…

Bench mate reunion at #GRCpancreas in Lucca Italy @DanielOhlund